Q: Can you provide details on the 10 new products and their expected release timeline? A: Todd Ashurst explained that product development takes about six months. The 10 new products are expected to be released gradually, with all products available by the start of quarter three. Each product undergoes independent testing to ensure quality and functionality.
Q: Is there any information on impairment reversal and its impact on financials? A: Martyn Dominy, CFO, noted that previously impaired products have been sold, leading to a positive impact on EBITDA. The company continues efforts to move superseded stock.
Q: What does the term "turnaround" mean to management, and will cost-saving measures continue? A: Todd Ashurst emphasized that the company has implemented long-term, policy-driven fixes to ensure efficient operations and cost management, and they will continue to focus on these measures.
Q: Are both business divisions now generating positive EBITDA, and are corporate costs covered? A: Martyn Dominy confirmed that both divisions are generating positive EBITDA, covering corporate costs. The company has aggressively reduced costs and is operating with a lean and agile approach.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.